IL307990A - Antimicrobial and anticancer agents - Google Patents

Antimicrobial and anticancer agents

Info

Publication number
IL307990A
IL307990A IL307990A IL30799023A IL307990A IL 307990 A IL307990 A IL 307990A IL 307990 A IL307990 A IL 307990A IL 30799023 A IL30799023 A IL 30799023A IL 307990 A IL307990 A IL 307990A
Authority
IL
Israel
Prior art keywords
subject
cancer
compound
pharmaceutical composition
administering
Prior art date
Application number
IL307990A
Other languages
English (en)
Hebrew (he)
Inventor
Hanns Moehler
James C Costin
Thomas Mueller
Original Assignee
Geistlich Pharma Ag
Hanns Moehler
James C Costin
Thomas Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Pharma Ag, Hanns Moehler, James C Costin, Thomas Mueller filed Critical Geistlich Pharma Ag
Publication of IL307990A publication Critical patent/IL307990A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL307990A 2021-04-29 2022-04-28 Antimicrobial and anticancer agents IL307990A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163181492P 2021-04-29 2021-04-29
PCT/IB2022/053973 WO2022229907A1 (en) 2021-04-29 2022-04-28 Antimicrobial and anticancer agents

Publications (1)

Publication Number Publication Date
IL307990A true IL307990A (en) 2023-12-01

Family

ID=81598080

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307990A IL307990A (en) 2021-04-29 2022-04-28 Antimicrobial and anticancer agents

Country Status (9)

Country Link
US (1) US12612375B2 (cg-RX-API-DMAC7.html)
EP (1) EP4330238A1 (cg-RX-API-DMAC7.html)
JP (1) JP7900637B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240004303A (cg-RX-API-DMAC7.html)
CN (1) CN117295720A (cg-RX-API-DMAC7.html)
AU (1) AU2022267897A1 (cg-RX-API-DMAC7.html)
CA (1) CA3216783A1 (cg-RX-API-DMAC7.html)
IL (1) IL307990A (cg-RX-API-DMAC7.html)
WO (1) WO2022229907A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024177036A1 (ja) * 2023-02-20 2024-08-29 大鵬薬品工業株式会社 Ftd・tpi配合剤、pd-1経路アンタゴニスト、及びvegf経路アンタゴニストの併用
WO2026074499A1 (en) * 2024-10-03 2026-04-09 Geistlich Pharma Ag Methods and compositions for inhibiting c-myc

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1160443B (de) 1961-11-30 1964-01-02 Hoechst Ag Verfahren zur Herstellung von Tetrahydro-oxathiazin-dioxyden
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US9241943B2 (en) * 2012-06-18 2016-01-26 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
SMT202200091T1 (it) * 2014-12-19 2022-03-21 Geistlich Pharma Ag Processi per preparare composti simili a ossatiazina
US20220313702A1 (en) * 2019-05-22 2022-10-06 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh

Also Published As

Publication number Publication date
EP4330238A1 (en) 2024-03-06
KR20240004303A (ko) 2024-01-11
US12612375B2 (en) 2026-04-28
CA3216783A1 (en) 2022-11-03
CN117295720A (zh) 2023-12-26
WO2022229907A1 (en) 2022-11-03
US20240199563A1 (en) 2024-06-20
JP7900637B2 (ja) 2026-08-05
AU2022267897A1 (en) 2023-11-02
JP2024515215A (ja) 2024-04-05

Similar Documents

Publication Publication Date Title
RU2508110C2 (ru) КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
US6635666B2 (en) Cancer treatment with epothilones
ZA200509515B (en) Pharmaceutical composition containing histone deacetylase inhibitor
RU2010117635A (ru) Комбинированная химиотерапия
US20220000835A1 (en) Method for treating cancer with a combination of quercetin and a chemotherapy agent
JP2003533485A5 (cg-RX-API-DMAC7.html)
RS58608B1 (sr) Kombinovana terapija sa antitumorskim antibiotikom
JP2005509599A (ja) 抗癌組み合わせ
Spalding et al. New and emerging radiosensitizers and radioprotectors
WO2006065780A2 (en) Combinations of therapeutic agents for treating cancer
KR20100126479A (ko) 개선된 항종양 치료법들
Adjei Current status of pyrazoloacridine as an anticancer agent
MX2008014404A (es) Tratamientos anticancer con combinacion de docetaxel y ecteinascidin.
Belani Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma
JP2024515215A5 (cg-RX-API-DMAC7.html)
US20200405752A1 (en) Antitumor agent, antitumor effect enhancer, and antitumor kit
US20030045562A1 (en) Treatment of inflammatory, cancer, and thrombosis disorders
CN110522753A (zh) 一种新型抗肿瘤药物组合物、制剂和应用
US20090281105A1 (en) Radiotherapy enhancer
ZA200200889B (en) Combination therapy using pentafluorobenzenesulfonamides.
Fracasso et al. Phase I study of rubitecan and gemcitabine in patients with advanced malignancies
CA3303218A1 (en) Cancer therapy comprising 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor
RU2026108802A (ru) Терапия рака, включающая соединение 3,5-дизамещенного бензолалкинила и ингибитор иммунных контрольных точек
Cervantes et al. State of the art treatment for gastric cancer: future directions
WO2010081825A2 (en) Pirenzepine as an agent in cancer treatment